{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:44:42Z","timestamp":1764873882556,"version":"3.44.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.pcl.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T20:04:20Z","timestamp":1637006660000},"page":"19-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Updates in Pediatric Tuberculosis in International Settings"],"prefix":"10.1016","volume":"69","author":[{"given":"Sadia","family":"Shakoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"first-page":"2020","year":"2020","series-title":"Global tuberculosis report 2020","key":"10.1016\/j.pcl.2021.09.004_bib1"},{"issue":"10228","key":"10.1016\/j.pcl.2021.09.004_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(20)30532-8","article-title":"No time to waste: preventing tuberculosis in children","volume":"395","author":"Campbell","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib3","first-page":"010423","article-title":"Health systems performance in managing tuberculosis: analysis of tuberculosis care cascades among high-burden and non-high-burden countries","volume":"9","author":"Kim","year":"2019","journal-title":"J\u00a0Glob Health"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-021-06398-0","article-title":"Health system determinants of tuberculosis mortality in South Africa: a causal loop model","volume":"21","author":"Osman","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"10.1016\/j.pcl.2021.09.004_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S2213-2600(21)00161-2","article-title":"Challenges and opportunities to end tuberculosis in the COVID-19 era","volume":"9","author":"Wingfield","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.pcl.2021.09.004_bib6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(16)30132-3","article-title":"Global burden of drug-resistant tuberculosis in children: a mathematical modelling study","volume":"16","author":"Dodd","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"9928","key":"10.1016\/j.pcl.2021.09.004_bib7","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(14)60195-1","article-title":"Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates","volume":"383","author":"Jenkins","year":"2014","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.pcl.2021.09.004_bib8","doi-asserted-by":"crossref","first-page":"e1002591","DOI":"10.1371\/journal.pmed.1002591","article-title":"Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis","volume":"15","author":"Harausz","year":"2018","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.pcl.2021.09.004_bib9","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/cid\/cix561","article-title":"Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993\u20132014","volume":"65","author":"Smith","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.pcl.2021.09.004_bib10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","article-title":"Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis","volume":"14","author":"Chiang","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.pcl.2021.09.004_bib11","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1473-3099(19)30162-8","article-title":"Severe disseminated tuberculosis in HIV-negative refugees","volume":"19","author":"Suarez","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MD.0b013e318030b605","article-title":"Disseminated tuberculosis: a 10-year experience in a medical center","volume":"86","author":"Wang","year":"2007","journal-title":"Medicine"},{"key":"10.1016\/j.pcl.2021.09.004_bib13","first-page":"27","article-title":"Tuberculosis in pregnant women and neonates: A meta-review of current evidence","volume":"36","author":"Snow","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"9","key":"10.1016\/j.pcl.2021.09.004_bib14","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1016\/S2214-109X(17)30289-9","article-title":"The global burden of tuberculosis mortality in children: a mathematical modelling study","volume":"5","author":"Dodd","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.pcl.2021.09.004_bib18","doi-asserted-by":"crossref","unstructured":"Chiang C-Y, Bam TS. Should tobacco control intervention be implemented into tuberculosis control program? In: Taylor & Francis; 2018.","DOI":"10.1080\/17476348.2018.1481394"},{"issue":"Suppl 2","key":"10.1016\/j.pcl.2021.09.004_bib19","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1542\/peds.2007-2022KKKKKK","article-title":"Prevalence of tuberculosis among children who had type 1 diabetes and were admitted to Elminia University Hospital","volume":"121","author":"Abdelmoez","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib20","first-page":"63","article-title":"Emerging dynamics of substance abuse among street children in Zimbabwe. A case of Harare Central Business District","volume":"8","author":"Jakaza","year":"2018","journal-title":"Afr J Soc Work"},{"year":"2016","series-title":"Health knowledge, attitudes, and practices among street children in LMICs","author":"Martyn","key":"10.1016\/j.pcl.2021.09.004_bib21"},{"issue":"3","key":"10.1016\/j.pcl.2021.09.004_bib22","first-page":"167","article-title":"British Infection Society. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children","volume":"59","author":"Thwaites","year":"2009","journal-title":"J\u00a0Infect"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10096-015-2507-6","article-title":"Recommendations for the diagnosis of pediatric tuberculosis","volume":"35","author":"Chiappini","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib24","first-page":"155","article-title":"Validity of symptoms and radiographic features in predicting positive AFB smears in adolescents with tuberculosis","volume":"14","author":"Wong","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"suppl_3","key":"10.1016\/j.pcl.2021.09.004_bib25","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/civ581","article-title":"Clinical case definitions for classification of intrathoracic tuberculosis in children: an update","volume":"61","author":"Graham","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2021.09.004_bib26","unstructured":"Organization WH. Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication. 2020."},{"key":"10.1016\/j.pcl.2021.09.004_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12688\/gatesopenres.12842.1","article-title":"Market penetration of Xpert MTB\/RIF in high tuberculosis burden countries: a trend analysis from 2014-2016","volume":"2","author":"Cazabon","year":"2018","journal-title":"Gates Open Res"},{"issue":"10133","key":"10.1016\/j.pcl.2021.09.004_bib28","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/S0140-6736(18)30459-8","article-title":"Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions","volume":"391","author":"Sayed","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/ijmy.ijmy_8_19","article-title":"Common alternative diagnoses among a pediatric hospital-based cohort evaluated for tuberculosis in Karachi, Pakistan: The need for facilitated referral in tuberculosis clinics","volume":"8","author":"Shakoor","year":"2019","journal-title":"Int J Mycobacteriol"},{"year":"2019","series-title":"Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update 2019","key":"10.1016\/j.pcl.2021.09.004_bib30"},{"issue":"9","key":"10.1016\/j.pcl.2021.09.004_bib31","doi-asserted-by":"crossref","first-page":"e0204029","DOI":"10.1371\/journal.pone.0204029","article-title":"Biomarkers for diagnosis of childhood tuberculosis: A systematic review","volume":"13","author":"Togun","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib32","doi-asserted-by":"crossref","first-page":"a018531","DOI":"10.1101\/cshperspect.a018531","article-title":"Toward a unified biosignature for tuberculosis","volume":"5","author":"Maertzdorf","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.pcl.2021.09.004_bib33","doi-asserted-by":"crossref","first-page":"102977","DOI":"10.1016\/j.ebiom.2020.102977","article-title":"Biosignatures: The answer to Tuberculosis diagnosis in children?","volume":"60","author":"Goussard","year":"2020","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.pcl.2021.09.004_bib34","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S1473-3099(20)30177-8","article-title":"Advanced imaging tools for childhood tuberculosis: potential applications and research needs","volume":"20","author":"Jain","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.prrv.2007.04.008","article-title":"Clinical manifestations of tuberculosis in children","volume":"8","author":"Cruz","year":"2007","journal-title":"Paediatr Respir Rev"},{"issue":"3","key":"10.1016\/j.pcl.2021.09.004_bib36","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1542\/peds.2008-1722","article-title":"Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents","volume":"123","author":"Bergamini","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.pcl.2021.09.004_bib37","first-page":"401896","article-title":"A\u00a0systematic review of clinical diagnostic systems used in the diagnosis of tuberculosis in children","volume":"2012","author":"Pearce","year":"2012","journal-title":"AIDS Res Treat"},{"key":"10.1016\/j.pcl.2021.09.004_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijid.2017.01.038","article-title":"A\u00a0comparison of tuberculosis diagnostic systems in a retrospective cohort of HIV-infected children in Rio de Janeiro, Brazil","volume":"59","author":"David","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.pcl.2021.09.004_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2017.03.009","article-title":"New optimism to the use of clinical scoring systems for the diagnosis of child tuberculosis\u2013even among HIV co-infected","volume":"59","author":"Holm","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"12","key":"10.1016\/j.pcl.2021.09.004_bib40","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1377\/hlthaff.2011.1356","article-title":"In urban and rural India, a standardized patient study showed low levels of provider training and huge quality gaps","volume":"31","author":"Das","year":"2012","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.pcl.2021.09.004_bib41","unstructured":"Organization WH. Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017."},{"year":"2014","series-title":"Guidance for national tuberculosis programmes on the management of tuberculosis in children","key":"10.1016\/j.pcl.2021.09.004_bib42"},{"issue":"5","key":"10.1016\/j.pcl.2021.09.004_bib43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.5588\/ijtld.15.0288","article-title":"Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children","volume":"20","author":"Mukherjee","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.pcl.2021.09.004_bib44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bcp.13846","article-title":"Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India","volume":"85","author":"Aruldhas","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pcl.2021.09.004_bib45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/jac\/dku478","article-title":"Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study","volume":"70","author":"Hiruy","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.pcl.2021.09.004_bib46","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1183\/09031936.00180612","article-title":"Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis","volume":"42","author":"Albanna","year":"2013","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.pcl.2021.09.004_bib47","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1128\/AAC.05429-11","article-title":"Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations","volume":"55","author":"Thee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.pcl.2021.09.004_bib48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/598192","article-title":"Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines","volume":"48","author":"McIlleron","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.pcl.2021.09.004_bib49","doi-asserted-by":"crossref","first-page":"e0213718","DOI":"10.1371\/journal.pone.0213718","article-title":"High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre","volume":"14","author":"Seijger","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dku382","article-title":"Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir\/ritonavir","volume":"70","author":"Moultrie","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"17","key":"10.1016\/j.pcl.2021.09.004_bib51","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2021.09.004_bib52","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.pcl.2021.09.004_bib53","doi-asserted-by":"crossref","first-page":"e67030","DOI":"10.1371\/journal.pone.0067030","article-title":"Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients","volume":"8","author":"Jawahar","year":"2013","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.pcl.2021.09.004_bib54","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2021.09.004_bib55","unstructured":"Organization WH. Treatment of drug-susceptible tuberculosis: rapid communication. 2021."},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-018-2608-5","article-title":"Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial","volume":"19","author":"Chabala","year":"2018","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.pcl.2021.09.004_bib58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1542\/peds.2014-1652","article-title":"Improving tuberculosis care for children in high-burden settings","volume":"134","author":"Starke","year":"2014","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.pcl.2021.09.004_bib59","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/infdis\/jis608","article-title":"Childhood tuberculosis and malnutrition","volume":"206","author":"Jaganath","year":"2012","journal-title":"J\u00a0Infect Dis"},{"issue":"10","key":"10.1016\/j.pcl.2021.09.004_bib60","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.200511-1809SO","article-title":"Childhood pulmonary tuberculosis: old wisdom and new challenges","volume":"173","author":"Marais","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.pcl.2021.09.004_bib61","doi-asserted-by":"crossref","first-page":"800","DOI":"10.5588\/ijtld.12.0628","article-title":"Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children","volume":"17","author":"Ramachandran","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.pcl.2021.09.004_bib62","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijantimicag.2017.12.004","article-title":"Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India","volume":"51","author":"Ranjalkar","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"25","key":"10.1016\/j.pcl.2021.09.004_bib63","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"Morb Mortal Wkly Rep"},{"year":"2015","series-title":"Guidelines on the management of latent tuberculosis infection","key":"10.1016\/j.pcl.2021.09.004_bib64"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib65","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/jpids\/pit077","article-title":"Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection","volume":"3","author":"Weiner","year":"2014","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"10.1016\/j.pcl.2021.09.004_bib66","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis","volume":"17","author":"Ferebee","year":"1969","journal-title":"Adv Tuberc Res"},{"issue":"5","key":"10.1016\/j.pcl.2021.09.004_bib67","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.1974.03230430020019","article-title":"Isoniazid in the prevention and treatment of tuberculosis: a 20-year study of the effectiveness in children","volume":"229","author":"Hsu","year":"1974","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.pcl.2021.09.004_bib68","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib69","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/jac\/dks395","article-title":"Is there a place for \u03b2-lactams in the treatment of multidrug-resistant\/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin\/clavulanate","volume":"68","author":"Gonzalo","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"year":"2014","series-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","key":"10.1016\/j.pcl.2021.09.004_bib70"},{"issue":"3","key":"10.1016\/j.pcl.2021.09.004_bib71","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1415332","article-title":"Delamanid for extensively drug-resistant tuberculosis","volume":"373","author":"Gupta","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.pcl.2021.09.004_bib72","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2021.09.004_bib73","unstructured":"Organization WH. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. 2016."},{"key":"10.1016\/j.pcl.2021.09.004_bib74","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijid.2016.10.021","article-title":"Applicability of the shorter \u2018Bangladesh regimen\u2019 in high multidrug-resistant tuberculosis settings","volume":"56","author":"Sotgiu","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.pcl.2021.09.004_bib75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis","volume":"6","author":"Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"year":"2018","series-title":"WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis","key":"10.1016\/j.pcl.2021.09.004_bib76"},{"issue":"5","key":"10.1016\/j.pcl.2021.09.004_bib77","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/thoraxjnl-2013-203900","article-title":"High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study","volume":"69","author":"Seddon","year":"2014","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.pcl.2021.09.004_bib78","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13312-019-1503-9","article-title":"What is new in management of pediatric tuberculosis?","volume":"56","author":"Khurana","year":"2019","journal-title":"Indian Pediatr"},{"year":"2017","series-title":"WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis","key":"10.1016\/j.pcl.2021.09.004_bib79"},{"year":"2020","series-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment","key":"10.1016\/j.pcl.2021.09.004_bib80"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-15-353","article-title":"Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial","volume":"15","author":"Nunn","year":"2014","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.pcl.2021.09.004_bib82","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.pcl.2021.09.004_bib83","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5588\/ijtld.17.0498","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"Tr\u00e9bucq","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.pcl.2021.09.004_bib85","unstructured":"Organization WH. Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary results. 2018."},{"key":"10.1016\/j.pcl.2021.09.004_bib86","unstructured":"Dara M, Zaleskis R, Acosta C, et\u00a0al. The role of surgery in the treatment of pulmonary TB and multidrug-and extensively drug-resistant TB. 2014."},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5588\/ijtld.12.0198","article-title":"Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"17","author":"Marrone","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"10.1016\/j.pcl.2021.09.004_bib88","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1586\/eri.12.108","article-title":"Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis","volume":"10","author":"Pontali","year":"2012","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib89","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/ejcts\/ezs215","article-title":"Surgical treatment to increase the success rate of multidrug-resistant tuberculosis","volume":"42","author":"Man","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"issue":"11","key":"10.1016\/j.pcl.2021.09.004_bib90","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-3156.2009.02375.x","article-title":"Toxicity of first-line drugs for treatment of tuberculosis in children","volume":"14","author":"Frydenberg","year":"2009","journal-title":"Trop Med Int Health"},{"issue":"10","key":"10.1016\/j.pcl.2021.09.004_bib91","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1164\/rccm.201206-1001CI","article-title":"Caring for children with drug-resistant tuberculosis: practice-based recommendations","volume":"186","author":"Seddon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"year":"2010","series-title":"Treatment of tuberculosis: guidelines","key":"10.1016\/j.pcl.2021.09.004_bib92"},{"key":"10.1016\/j.pcl.2021.09.004_bib93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ebiom.2016.08.040","article-title":"NAT2 Genotype and isoniazid medication in children","volume":"11","author":"Golka","year":"2016","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.pcl.2021.09.004_bib94","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1389557515666150722101723","article-title":"Advances in drug discovery and development for pediatric tuberculosis","volume":"16","author":"Hoagland","year":"2016","journal-title":"Mini Rev Med Chem"},{"issue":"7","key":"10.1016\/j.pcl.2021.09.004_bib95","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01567-09","article-title":"Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used","volume":"54","author":"Pasipanodya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib96","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<37::AID-PPUL8>3.0.CO;2-G","article-title":"Hepatic enzyme abnormalities in children on triple therapy for tuberculosis","volume":"27","author":"Corrigan","year":"1999","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib97","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prrv.2007.04.001","article-title":"Old and new drugs for the treatment of tuberculosis in children","volume":"8","author":"Donald","year":"2007","journal-title":"Paediatr Respir Rev"},{"issue":"6","key":"10.1016\/j.pcl.2021.09.004_bib98","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(12)70033-6","article-title":"Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Ettehad","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib99","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tube.2011.11.001","article-title":"Paediatric use of second-line anti-tuberculosis agents: a review","volume":"92","author":"Seddon","year":"2012","journal-title":"Tuberculosis"},{"issue":"5","key":"10.1016\/j.pcl.2021.09.004_bib100","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s10903-015-0273-2","article-title":"Latent tuberculosis infection among immigrant and refugee children arriving in the United States: 2010","volume":"18","author":"Taylor","year":"2016","journal-title":"J\u00a0Immigr Minor Health"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-05828-y","article-title":"Tuberculosis (TB) in the refugee camps in Ethiopia: trends of case notification, profile, and treatment outcomes, 2014 to 2017","volume":"21","author":"Legesse","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.pcl.2021.09.004_bib102","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jfma.2011.11.004","article-title":"Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs)","volume":"110","author":"Lee","year":"2011","journal-title":"J\u00a0Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib103","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1086\/321999","article-title":"Interleukin-12 receptor \u03b21 deficiency in a patient with abdominal tuberculosis","volume":"184","author":"Altare","year":"2001","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.pcl.2021.09.004_bib104","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/375587","article-title":"Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor \u03b21 deficiency","volume":"37","author":"Caragol","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.pcl.2021.09.004_bib105","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1086\/427879","article-title":"Interleukin-12 receptor \u03b21 chain deficiency in a child with disseminated tuberculosis","volume":"40","author":"\u00d6zbek","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.pcl.2021.09.004_bib106","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1016\/S2214-109X(14)70330-4","article-title":"Tuberculosis in pregnancy: an estimate of the global burden of disease","volume":"2","author":"Sugarman","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1101-x","article-title":"Diagnosis and treatment of congenital tuberculosis: a systematic review of 92 cases","volume":"14","author":"Li","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcl.2021.09.004_bib108","unstructured":"Organization WH. Roadmap towards ending TB in children and adolescents. 2018."},{"issue":"1","key":"10.1016\/j.pcl.2021.09.004_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0500-3-324","article-title":"Are children with tuberculosis in Pakistan managed according to National programme policy guidelines? A study from 3 districts in Punjab","volume":"3","author":"Safdar","year":"2010","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.pcl.2021.09.004_bib110","unstructured":"Organization WH. BCG Evidence to Recommendation Framework 2017."},{"issue":"24","key":"10.1016\/j.pcl.2021.09.004_bib111","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2018.03.009","article-title":"BCG vaccine: WHO position paper, February 2018\u2013recommendations","volume":"36","author":"Organization","year":"2018","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.pcl.2021.09.004_bib112","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1080\/21645515.2015.1074361","article-title":"Immunogenicity and safety of early vs delayed BCG vaccination in moderately preterm (31\u201333\u00a0weeks) infants","volume":"11","author":"Saroha","year":"2015","journal-title":"Hum Vaccines Immunother"},{"issue":"4","key":"10.1016\/j.pcl.2021.09.004_bib113","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1651-2227.1985.tb11030.x","article-title":"Tuberculin conversion following BCG vaccination in preterm infants","volume":"74","author":"Dawodu","year":"1985","journal-title":"Acta P\u00e6diatrica"},{"issue":"8","key":"10.1016\/j.pcl.2021.09.004_bib114","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10096-020-03843-6","article-title":"Tuberculosis vaccine development: from classic to clinical candidates","volume":"39","author":"Li","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pcl.2021.09.004_bib115","unstructured":"Mandalakas AM, Starke JR. Current concepts of childhood tuberculosis. Paper presented at: Seminars in pediatric infectious diseases. Geneva: World Health Organization, March 2-4, 2021."},{"issue":"7","key":"10.1016\/j.pcl.2021.09.004_bib116","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.pcl.2021.09.004_bib117","first-page":"CD006594","article-title":"Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment","author":"Liu","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pcl.2021.09.004_bib118","first-page":"CD007952","article-title":"Material incentives and enablers in the management of tuberculosis","volume":"1","author":"Lutge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pcl.2021.09.004_bib119","unstructured":"Organization WH. WHO consultation on the translation of tuberculosis research into global policy guidelines: 2-4 March 2021: meeting report. Geneva: World Health Organization, March 2-4, 2021."}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395521001462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395521001462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:26:20Z","timestamp":1758475580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395521001462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0031395521001462"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2021.09.004","relation":{},"ISSN":["0031-3955"],"issn-type":[{"type":"print","value":"0031-3955"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in Pediatric Tuberculosis in International Settings","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}